Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage

Aliment Pharmacol Ther. 2007 Jul 15;26(2):265-75. doi: 10.1111/j.1365-2036.2007.03358.x.

Abstract

Background: Upper gastrointestinal (UGI) complications are a well-recognized risk of NSAID treatment, requiring preventive measures in high-risk patients. Adherence to gastroprotective agents (GPAs) in NSAID users has been suggested to be suboptimal.

Aim: To investigate the association between adherence to GPAs (proton pump inhibitors or H(2)-receptor antagonists) and the risk of NSAID-related UGI ulcers or haemorrhage in high-risk patients.

Methods: A population-based nested case-control study was conducted within a cohort of new NSAID users with at least one risk factor for a NSAID-related UGI complication, identified in the Dutch IPCI database during 1996-2005. Adherence to GPAs was calculated as the proportion of NSAID treatment days covered (PDC) by a GPA prescription. Multivariate conditional logistic regression analysis was used to calculate odds ratios with 95% confidence intervals (95% CI).

Results: Fifteen percent of the non-selective NSAID users received GPAs. The risk of a NSAID-related UGI complication among NSAID users increased 16% for every 10% decrease in adherence. Compared to patients with a PDC of >80%, patients with PDCs of 20-80% and <20% had a 2.5-fold (95% CI: 1.0-6.7) respectively 4.0-fold (95% CI: 1.2-13.0) increased risk.

Conclusion: There is a strong inverse relationship between adherence to GPAs and the risk of UGI complications in high-risk NSAID users.

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Case-Control Studies
  • Drug Therapy, Combination
  • Female
  • Gastrointestinal Hemorrhage / chemically induced*
  • Histamine H2 Antagonists / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Netherlands
  • Peptic Ulcer / chemically induced*
  • Proton Pump Inhibitors*
  • Proton Pumps / adverse effects
  • Regression Analysis
  • Risk Factors
  • Upper Gastrointestinal Tract / drug effects*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Histamine H2 Antagonists
  • Proton Pump Inhibitors
  • Proton Pumps